Drug Information

Drug General Information
Drug ID
D0E5XA
Former ID
DCL000210
Drug Name
R763
Indication Haematological malignancies [ICD9: 200-209; ICD10:C81-C86] Phase 1 [549926]
Therapeutic Class
Anticancer Agents
Target and Pathway
Target(s) Aurora kinase B Target Info Inhibitor [537610]
Aurora kinase A Target Info Inhibitor [537610]
KEGG Pathway Oocyte meiosis
Pathway Interaction Database Aurora B signaling
Signaling by Aurora kinases
Aurora C signaling
FOXM1 transcription factor network
Aurora A signalingaurora_b_pathway:Aurora B signaling
Integrin-linked kinase signaling
PLK1 signaling events
Aurora A signaling
Reactome APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1
Separation of Sister Chromatids
Resolution of Sister Chromatid Cohesion
RHO GTPases Activate Formins
Mitotic PrometaphaseR-HSA-174178:APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1
Regulation of PLK1 Activity at G2/M Transition
WikiPathways Mitotic Metaphase and Anaphase
Mitotic Prometaphase
Regulation of Microtubule Cytoskeleton
miR-targeted genes in lymphocytes - TarBase
miR-targeted genes in epithelium - TarBase
APC/C-mediated degradation of cell cycle proteinsWP437:EGF/EGFR Signaling Pathway
JAK/STAT
Gastric Cancer Network 1
Integrated Breast Cancer Pathway
APC/C-mediated degradation of cell cycle proteins
References
Ref 549926Clinical pipeline report, company report or official report of Rigel.
Ref 537610Preclinical characterization of Aurora kinase inhibitor R763/AS703569 identified through an image-based phenotypic screen. J Cancer Res Clin Oncol. 2009 Jul 17.